Latest Breaking News On - வள வலைப்பின்னல் - Page 1 : comparemela.com
OTHRStore to Deliver an Ecosystem of Services for Underrepresented Food and Beverage Brands in the Digital Marketplace
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
New Columbus Police Chief Elaine Bryant attends community events
dispatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dispatch.com Daily Mail and Mail on Sunday newspapers.
Activist: Protection orders still ineffective
cnc3.co.tt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnc3.co.tt Daily Mail and Mail on Sunday newspapers.
Albireo s Bylvay approved in EU and US for rare paediatric liver disease
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
– Commercial launch of Bylvay immediate; available for prescription in the coming days –
– Rare Pediatric Disease Priority Review Voucher issued to Albireo by the FDA –
– Company to host investor conference call on July 21 at 8:30 a.m. ET –
BOSTON, July 20, 2021 (GLOBE NEWSWIRE) Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced U.S. Food & Drug Administration (FDA) approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), which does not require refrigeration and is easily administered as a once-daily capsule or opened and sprinkled onto soft foods. Albireo is launching Bylvay immediately to accelerate availability for the patients and families impacted by PFIC.